Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
11/2000
11/23/2000WO2000069860A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000WO2000069848A1 Compounds having cytokine inhibitory activity
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069831A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069821A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069819A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000WO2000069818A1 MORPHOLINO-N-ETHYL ESTER DERIVATIVE OF AN INDOLE sPLA2 INHIBITOR
11/23/2000WO2000069472A2 Enzyme-activated anti-tumor prodrug compounds
11/23/2000WO2000069449A2 Conditioned cell culture medium compositions and methods of use
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000043354A3 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000030681A9 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
11/23/2000WO2000023053A3 Artificial antigen-specific cells and related methods
11/23/2000WO1999061398A3 24-hydroxyvitamin d, analogs and uses thereof
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374235A1 Production of complex carbohydrates
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373532A1 Morpholino-n-ethyl ester derivative of an indole spla2 inhibitor
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372051A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2370066A1 Thiazolopyrimidines useful as tnf.alpha. inhibitors
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053750A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
11/22/2000EP1053332A1 Protein
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053226A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
11/22/2000EP1053002A1 Treatment of bony defects with osteoblast precursor cells
11/22/2000EP1053000A1 Agents and methods for protection, treatment and repair of connective tissue
11/22/2000EP1052986A1 Anti-inflammatory agents
11/22/2000EP0586535B1 Methods and compositions based on inhibition of cell invasion and fibrosis by dextran sulfate
11/22/2000CN1274344A Novel vitamin D analogues
11/22/2000CN1274288A Peptide-containing & alpha; -ketoamide cysteine and serine protease inhibitors
11/22/2000CN1274283A Quinoline-containing & Alpha;-ketoamide cysteine and serine protease inhibitors
11/22/2000CN1273857A Antalgic liquid for early stage of bone fracture and injury and ointment for its recovery stage
11/22/2000CN1058718C Optically active benzothiepin derivative, its prepn. and use
11/22/2000CN1058715C Thiophene compound, its prepn. method and medicinal compsn. containing same
11/21/2000US6150557 Compounds
11/21/2000US6150413 Treatment of dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as mammalian skin and hair conditions; 4-(4-(biphenyl-2-yl)but-3-en-1-ynyl)benzoic acid, for example
11/21/2000US6150407 In a tissue or organ by contacting with a compound of given formula such as methyl-3,5-diiodo-4-(4'-methoxyphenoxy)benzoate; reducing the level of tumor necrosis factor alpha
11/21/2000US6150378 Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
11/21/2000US6150346 Method and composition for treating or preventing osteoporosis
11/21/2000US6150325 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
11/21/2000US6149946 Method and product using sturgeon notochord for alleviating the symptoms of arthritis
11/16/2000WO2000068385A2 Novel nucleic acids and proteins with growth hormone activity
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068263A2 Stereoselective antifibrillogenic peptides and peptidomimetics thereof
11/16/2000WO2000068255A2 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
11/16/2000WO2000068247A2 Serine proteases
11/16/2000WO2000068246A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068205A1 Process for obtaining a hydroxamic acid
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068194A1 Iminocyclitol inhibitors of hexoaminidase and glycosidase
11/16/2000WO2000068188A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067764A2 Improved method for treating mammals with modified mammalian blood
11/16/2000WO2000067761A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000WO2000067752A1 Use of succinic acid derivatives to obtain a medicine for treating inflammation
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067736A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000050045A3 Solution for injection containing a gold compound, calendula and belladonna extracts for the treatment of arthroses
11/16/2000WO2000048996A3 β-ALANINE DERIVATIVES
11/16/2000WO2000042168A3 Bifidobacterium in the treatment of inflammatory disease
11/16/2000WO2000041669A3 Benzimidazole vascular damaging agents
11/16/2000WO2000041469A3 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000034331A3 Analogues of glp-1
11/16/2000WO2000027887A3 Cross-linked hyaluronic acids and medical uses thereof
11/16/2000WO2000027377A3 Phosphinate peptide analogs for the treatment of fibrotic disorders
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000CA2388092A1 Stereoselective antifibrillogenic peptides and peptidomimetics thereof
11/16/2000CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000CA2373759A1 Serine proteases
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2372871A1 Novel nucleic acids and proteins with growth hormone activity
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
1 ... 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 ... 820